{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-038867","form_type":"8-K","ticker":"ARWR","cik":"0000879407","company_name":"ARROWHEAD PHARMACEUTICALS, INC.","filed_at":"2025-08-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:46.552087+00:00","generated_at":"2026-05-17T18:42:49.027919+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Arrowhead Q3 revenue $27.8M, net loss $1.26/sh; plozasiran PDUFA Nov 18, 2025","bullets":["Revenue $27.8M (vs $0 YoY); net loss attributable $175.2M, or $1.26 diluted EPS (vs $1.38).","Cash & securities $900.4M; credit facility $240.3M; liability from royalty sale $360.3M.","Sanofi to pay Visirna $130M upfront for Greater China license to plozasiran; up to $265M milestones.","Earned $100M milestone from Sarepta; second enrollment target for ARO-DM1 may trigger $200M by end-2025.","Plozasiran NDA accepted with PDUFA date Nov 18, 2025; Phase 3 SHASTA-3/4 and MUIR-3 fully enrolled."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-038867","json":"https://secwatch.observer/filing/0001628280-25-038867.json","markdown":"https://secwatch.observer/filing/0001628280-25-038867.md","text":"https://secwatch.observer/filing/0001628280-25-038867.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/879407/000162828025038867/0001628280-25-038867-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/879407/000162828025038867/arwr-20250807.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:42:49.027919+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}